- In March 2022, a report from the International Agency for the Prevention of Blindness outlined significant challenges in the uveitis drug sector, including gaps in early diagnosis, high treatment costs, and the complexity of managing chronic and recurrent forms of the disease.
- The report highlighted the growing importance of targeted biologics, intravitreal delivery systems, and personalized medicine in reducing relapses and improving long-term outcomes. Industry focus is increasingly shifting toward non-steroidal alternatives and disease-modifying therapies to minimize adverse effects and enhance patient quality of life.
